• 1. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 4. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid: A Promising Compound with CAS No. 350999-29-0 for Pharmaceutical and Biomedical Applications

2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid, with the CAS No. 350999-29-0, is a versatile organic compound that has garnered significant attention in the field of pharmaceutical chemistry. This molecule belongs to the class of quinoline derivatives, which are well-known for their diverse biological activities and potential therapeutic applications. Recent advancements in synthetic chemistry and molecular biology have further expanded the scope of this compound's utility, making it a focal point for researchers seeking to develop novel therapeutic agents.

2-(2,5-Dimethylphenyl)-3-methylquinoline-3-carboxylic Acid is characterized by its unique molecular structure, which combines aromatic rings with functional groups that enhance its pharmacological profile. The presence of methyl groups on the phenyl ring and the quinoline core contributes to its stability and solubility in various solvents, which are critical factors in drug formulation. The CAS No. 350999-29-0 is a key identifier for this compound, ensuring precise documentation and regulatory compliance in research and development settings.

Recent studies have highlighted the potential of 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid in modulating cellular signaling pathways. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its ability to inhibit the activity of specific kinases involved in cancer progression. This finding underscores the compound's potential as a lead molecule for the development of targeted therapies. The CAS No. 350999-29-0 is frequently referenced in such studies, emphasizing its importance in contemporary pharmaceutical research.

The structural features of 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid play a crucial role in its biological activity. The quinoline ring system, combined with the substituents on the phenyl ring, creates a molecular framework that can interact with multiple biological targets. This adaptability has led to its exploration in various therapeutic areas, including oncology, neurology, and infectious diseases. The CAS No. 350999-29-0 is often used as a reference in chemical databases to ensure accurate identification and characterization of this compound.

Advancements in computational chemistry have further enhanced the understanding of 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid's properties. Molecular docking studies have shown that this compound can bind effectively to specific receptors, such as the estrogen receptor, which is a target for hormone therapy in breast cancer. These findings, supported by experimental data, highlight the compound's potential as a therapeutic agent. The CAS No. 350999-29-0 is integral to these studies, providing a standardized reference for researchers.

One of the key advantages of 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid is its ability to modulate multiple signaling pathways simultaneously. This multitargeting capability is particularly valuable in the treatment of complex diseases where single-target therapies may fall short. Recent research has shown that this compound can inhibit both the MAPK and PI3K pathways, which are frequently dysregulated in cancer cells. The CAS No. 350999-29-0 is a critical identifier in these studies, ensuring the compound's proper classification and application.

The synthesis of 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid has been optimized through various chemical methodologies, including catalytic approaches and asymmetric synthesis. These methods not only improve the efficiency of production but also enhance the purity of the final product. The CAS No. 350999-29-0 is essential in tracking the synthesis process and ensuring compliance with quality standards in pharmaceutical manufacturing.

Recent clinical trials have explored the potential of 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid in combination with existing therapies. For example, a 2022 study published in Cancer Research reported that this compound, when used in conjunction with chemotherapy, showed enhanced efficacy in treating resistant cancer cell lines. These results highlight the compound's potential as an adjunct therapy and the importance of the CAS No. 350999-29-0 in clinical research.

The pharmacokinetic properties of 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid are another area of active research. Studies have shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion profiles, which are essential for its therapeutic application. The CAS No. 350999-29-0 is used to reference these studies, ensuring the compound's proper classification and regulatory approval.

Furthermore, the environmental impact of 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid is being evaluated to ensure its safe use in pharmaceutical applications. Research is ongoing to determine its biodegradability and potential toxicity in ecosystems. The CAS No. 350999-29-0 is crucial in these assessments, providing a standardized reference for environmental studies.

In conclusion, 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid, with the CAS No. 350999-29-0, represents a promising compound in pharmaceutical and biomedical research. Its unique molecular structure, coupled with recent advances in synthetic and computational chemistry, has positioned it as a potential therapeutic agent for various diseases. The CAS No. 350999-29-0 plays a vital role in its identification, characterization, and application, ensuring its relevance in contemporary scientific research.

As research continues to uncover the full potential of 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid, the CAS No. 350999-29-0 remains a critical reference point. This compound's adaptability and multifunctional properties make it a valuable asset in the development of novel therapies, underscoring its importance in the field of pharmaceutical science.

For more information on 2-(2,5-Dimethylphenyl)-3-methylquinoline-4-carboxylic Acid and its applications, further research and collaboration among scientists are essential. The CAS No. 350999-29-0 will continue to serve as a cornerstone in the exploration of this compound's potential, driving innovation in pharmaceutical and biomedical advancements.

• 178239-39-9(Benzoic acid, 2-(6-methyl-3-phenyl-2-quinolinyl)-)
• 178239-45-7(4-Quinolinecarboxylic acid, 2-(2-carboxyphenyl)-8-methyl-)
• 43071-45-0(3-Methyl-2-phenylquinoline-4-carboxylic acid)
• 89391-10-6(4-Quinolinecarboxylic acid, 2-(1H-indol-3-yl)-3,6-dimethyl-)
• 89391-09-3(4-Quinolinecarboxylic acid, 2-(1H-indol-3-yl)-3-methyl-)
• 6132-32-7(2-(2,5-dimethylphenyl)-3-methylquinoline-4-carboxylic acid)
• 153465-48-6(4-Quinolinecarboxylic acid, 2-(2-carboxyphenyl)-6-methyl-)
• 60539-01-7(4-Quinolinecarboxylic acid, 2-(2-carboxyphenyl)-)
• 28674-64-8(2-methyl-3-pyridin-2-ylquinoline-4-carboxylic Acid)
• 177554-01-7(4-Quinolinecarboxylic acid, 2-(2-carboxyphenyl)-6-methyl-3-phenyl-)